喷昔洛韦联合干扰素α-1b治疗重症带状疱疹临床效果及安全性

Combined therapy of penciclovir with interferon α-1b in treatment of severe herpes zoster: effect and safety

目的探讨喷昔洛韦联合干扰素α-1b治疗重症带状疱疹的临床效果及安全性。方法将74例重症带状疱疹患者随机分为两组,各37例。对照组给予喷昔洛韦治疗,观察组在对照组基础上加用干扰素α-1b治疗,对比两组治疗效果及不良反应等。结果治疗后,观察组疼痛缓解时间、止疱时间、皮损消退时间及50%皮损结痂时间均短于对照组(P<0.01);治疗15 d后,两组治疗效果差异无统计学意义(P>0.05);两组用药期间均无严重药物不良反应发生;随访3个月,观察组后遗神经痛(PHN)发生率为9.09%,低于对照组的29.03%(P<0.05)。结论喷昔洛韦联合干扰素α-1b治疗重症带状疱疹安全有效,可缩短病程,减少PHN的发生率。

Objective To investigate the curative effect and safety of the combination therapy of penciclovir with interferon α-1b in treatment of severe herpes zoster .Methods Seventy-four patients with severe herpes zoster were divided into the observation group （ n =37）and the control group（ n =37）,and the control group was given penciclovir injection ,and the observation group was given additional interferon α-1b muscle injection,and curative effect of the two groups were observed .Results Pain relief time,blister check time,lesions subsiding time and 50% skin crusting time of the observation group after treatment were significantly shorter than that of the control group（ P 0.05）.No serious adverse drug reactions occurred during the medication .The incidence rate of neuralgia （PHN）of the observation group was 9.09%,lower than 29.03%of the control group（ P 〈0.05）.Conclusion Penciclovir with interferon α-1b in treatment of severe herpes zoster is safe and effective and can significantly shorten the course of the disease and reduce the incidence rate of PHN.